Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy-Reference-Cited by-同舟云学术

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

Published:2019-03-11 Issue:9 Volume:33 Page:2266-2275
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gandhi Ujjawal H.,Cornell Robert F.,Lakshman Arjun,Gahvari Zhubin J.,McGehee Elizabeth,Jagosky Megan H.,Gupta Ridhi,Varnado William,Fiala Mark A.,Chhabra Saurabh,Malek Ehsan,Mansour Joshua,Paul Barry,Barnstead Alyssa,Kodali Saranya,Neppalli Amarendra,Liedtke Michaela,Narayana Swapna,Godby Kelly N.,Kang Yubin,Kansagra Ankit^ORCID,Umyarova Elvira,Scott Emma C.,Hari Parameswaran,Vij Ravi,Usmani Saad Z.,Callander Natalie S.,Kumar Shaji K.^ORCID,Costa Luciano J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0435-7.pdf

Reference25 articles.

1. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947–59.

2. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8.

3. Moreau P. How I treat myeloma with new agents. Blood. 2017;130:1507–13.

4. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–19.

5. Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443–8.

Cited by 446 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

3. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma;Blood Cancer Journal;2024-09-05

4. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma;Current Medical Research and Opinion;2024-09-03

5. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis;European Journal of Haematology;2024-08-26